Ross Osborn
Stock Analyst at Cantor Fitzgerald
(2.15)
# 2,976
Out of 5,105 analysts
119
Total ratings
36.36%
Success rate
-1.65%
Average return
Main Sectors:
Stocks Rated by Ross Osborn
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CVRX CVRx, Inc. | Maintains: Overweight | $11 → $13 | $8.44 | +54.03% | 4 | Nov 6, 2025 | |
| PRE Prenetics Global | Maintains: Overweight | $26 → $32 | $14.86 | +115.42% | 8 | Oct 29, 2025 | |
| ORGO Organogenesis Holdings | Maintains: Overweight | $7 → $9 | $4.82 | +86.72% | 4 | Aug 8, 2025 | |
| LMAT LeMaitre Vascular | Maintains: Neutral | $92 → $95 | $84.00 | +13.10% | 2 | Aug 6, 2025 | |
| SIBN SI-BONE | Reiterates: Overweight | $25 | $18.59 | +34.48% | 10 | Aug 5, 2025 | |
| MDXG MiMedx Group | Maintains: Overweight | $11 → $12 | $7.23 | +65.98% | 5 | Jul 31, 2025 | |
| BVS Bioventus | Initiates: Overweight | $12 | $7.56 | +58.84% | 1 | Jul 7, 2025 | |
| XGN Exagen | Maintains: Overweight | $8 → $7 | $7.11 | -1.55% | 6 | May 15, 2025 | |
| LUCD Lucid Diagnostics | Reiterates: Overweight | $2 | $1.16 | +72.41% | 6 | May 15, 2025 | |
| NPCE NeuroPace | Reiterates: Overweight | $17 | $16.19 | +5.00% | 7 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $9 | $3.22 | +179.50% | 11 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $46 | $25.91 | +77.54% | 6 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $8 | $0.70 | +1,046.30% | 10 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $24 | $30.39 | -21.03% | 3 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $4 | $2.18 | +83.49% | 4 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $9 | $4.98 | +80.72% | 1 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $21 | $3.46 | +506.94% | 10 | Dec 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $16 | $4.73 | +238.27% | 4 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3.5 | $2.12 | +65.09% | 5 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $2.5 | $0.27 | +829.37% | 3 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $1.03 | - | 7 | Apr 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $8.61 | $0.33 | +2,509.09% | 2 | Aug 18, 2023 |
CVRx, Inc.
Nov 6, 2025
Maintains: Overweight
Price Target: $11 → $13
Current: $8.44
Upside: +54.03%
Prenetics Global
Oct 29, 2025
Maintains: Overweight
Price Target: $26 → $32
Current: $14.86
Upside: +115.42%
Organogenesis Holdings
Aug 8, 2025
Maintains: Overweight
Price Target: $7 → $9
Current: $4.82
Upside: +86.72%
LeMaitre Vascular
Aug 6, 2025
Maintains: Neutral
Price Target: $92 → $95
Current: $84.00
Upside: +13.10%
SI-BONE
Aug 5, 2025
Reiterates: Overweight
Price Target: $25
Current: $18.59
Upside: +34.48%
MiMedx Group
Jul 31, 2025
Maintains: Overweight
Price Target: $11 → $12
Current: $7.23
Upside: +65.98%
Bioventus
Jul 7, 2025
Initiates: Overweight
Price Target: $12
Current: $7.56
Upside: +58.84%
Exagen
May 15, 2025
Maintains: Overweight
Price Target: $8 → $7
Current: $7.11
Upside: -1.55%
Lucid Diagnostics
May 15, 2025
Reiterates: Overweight
Price Target: $2
Current: $1.16
Upside: +72.41%
NeuroPace
May 14, 2025
Reiterates: Overweight
Price Target: $17
Current: $16.19
Upside: +5.00%
Apr 1, 2025
Maintains: Overweight
Price Target: $12 → $9
Current: $3.22
Upside: +179.50%
Mar 26, 2025
Reiterates: Overweight
Price Target: $46
Current: $25.91
Upside: +77.54%
Mar 7, 2025
Reiterates: Overweight
Price Target: $8
Current: $0.70
Upside: +1,046.30%
Mar 5, 2025
Reiterates: Overweight
Price Target: $24
Current: $30.39
Upside: -21.03%
Feb 21, 2025
Reiterates: Overweight
Price Target: $4
Current: $2.18
Upside: +83.49%
Jan 7, 2025
Initiates: Overweight
Price Target: $9
Current: $4.98
Upside: +80.72%
Dec 24, 2024
Reiterates: Overweight
Price Target: $21
Current: $3.46
Upside: +506.94%
Nov 5, 2024
Reiterates: Overweight
Price Target: $16
Current: $4.73
Upside: +238.27%
Aug 8, 2024
Reiterates: Overweight
Price Target: $3.5
Current: $2.12
Upside: +65.09%
May 16, 2024
Reiterates: Overweight
Price Target: $2.5
Current: $0.27
Upside: +829.37%
Apr 12, 2024
Reiterates: Neutral
Price Target: n/a
Current: $1.03
Upside: -
Aug 18, 2023
Reiterates: Neutral
Price Target: $8.61
Current: $0.33
Upside: +2,509.09%